AtaiBeckley (ATAI) Cash from Investing Activities (2020 - 2026)
AtaiBeckley (ATAI) recorded quarterly Cash from Investing Activities of -$21.7 million in Q1 2026, down 96.6% quarter-over-quarter from -$11.0 million in Q1 2025, and down 96.6% on a YoY basis from -$636.0 million in Q1 2025.
AtaiBeckley (ATAI) Cash from Investing Activities (2020 - 2026) Analysis & Trends
AtaiBeckley has disclosed Cash from Investing Activities across 6 years of filings, most recently posting -$67.6 million for Q3 2025.
- Cash from Investing Activities for Q3 2025 came in at -$67.6 million, down 371.95% year-over-year; the trailing twelve-month figure through Sep 2025 was -$62.2 million (down 220.15% YoY), and the FY2024 annual result was $59.2 million, up 211.03% from the prior year.
- Cash from Investing Activities was -$21.7 million for Q1 2026 at AtaiBeckley, down from -$11.0 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$11.0 million in Q1 2025 to a low of -$21.7 million in Q1 2026.
- The 5-year median for Cash from Investing Activities is -$823000.0 (2023), against an average of -$12.2 million.
- Peak annual rise in Cash from Investing Activities reached 10857.33% in 2022, while the deepest fall reached 5670.92% in 2022.
- AtaiBeckley's Cash from Investing Activities stood at -$48.6 million in 2021, then surged by 264.6% to $80.1 million in 2022, then slumped by 101.03% to -$823000.0 in 2023, then soared by 897.08% to $6.6 million in 2024, then plunged by 1129.77% to -$67.6 million in 2025.
- The last three Cash from Investing Activities figures came in at -$67.6 million (Q3 2025), $9.8 million (Q2 2025), and -$11.0 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | -21.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.65 Mn |
| Mar 31, 2026 | -21.65 Mn |
| Sep 30, 2025 | -67.55 Mn |
| Sep 30, 2025 | -67.55 Mn |
| Jun 30, 2025 | 9.78 Mn |
| Jun 30, 2025 | 9.78 Mn |
| Mar 31, 2025 | -11.01 Mn |
| Mar 31, 2025 | -11.01 Mn |
| Mar 31, 2025 | -11.01 Mn |
| Mar 31, 2025 | -11.01 Mn |
| Dec 31, 2024 | 6.56 Mn |
| Dec 31, 2024 | 6.56 Mn |
| Sep 30, 2024 | 24.84 Mn |
| Sep 30, 2024 | 24.84 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Mar 31, 2024 | 11.47 Mn |
| Mar 31, 2024 | 11.47 Mn |
| Dec 31, 2023 | -823,000.00 |
| Dec 31, 2023 | -823,000.00 |